Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Soumitro Pal has a total of 88 co-authors. Here are the top co-authors by number of shared publications:

  • Aninda Basu

    Department of Dermatology, Division of Nephrology, Children’s Hospital Boston, MA

    11 shared publications
  • Murugabaskar Balan

    Division of Nephrology, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA

    9 shared publications
  • Dipak Datta

    Division of Nephrology and Transplantation Research Center, Children's Hospital Boston, Boston, MA

    8 shared publications
  • Akash Sabarwal

    Boston Children’s Hospital 1 Division of Nephrology Boston, Massachusetts

    7 shared publications
  • Evelyn Flynn

    Division of Nephrology, Boston Children’s Hospital, Boston, MA 02115, USA

    7 shared publications
  • Pallavi Banerjee

    Division of Nephrology, Children's Hospital, Boston, MA 02115, USA

    7 shared publications

Latest Publications

  • Inhibition of PLK1 Helps Restrict c-Met–Induced Growth and Therapeutic Resistance of Renal Cancer Cells

    by Laxminarayan Rawat, Chiranth M. Prakash, Yuzuru Sasamoto, Rahi Tinni Basu, Akash Sabarwal, Soumitro Pal

    Acquired therapeutic resistance is a major problem in the treatment of advanced renal cell carcinoma (RCC). The receptor tyrosine kinase (RTK) c-Met is hyperactive in RCC and plays a major role in the survival of tumor cells during therapy-induced oxidative stress. Although the c-Met/RTK inhibitor cabozantinib (cabo) has demonstrated efficacy in the treatment of RCC, therapeutic resistance significantly restricts its effectiveness. Thus, new target molecules and combination therapies need to be explored. Among several cell-cycle regulators, Polo-like kinase 1 (PLK1), which is overexpressed in RCC, can play a vital role in cancer progression. In this study, for the first time, we show that the activation of c-Met markedly promotes renal cancer cell growth and proliferation through PLK1. We found that a novel combination treatment with cabo and a PLK1 inhibitor (onvansertib) induces dual-phase cell-cycle arrest at both G1 and G2–M checkpoints and impairs RCC cell migration. It induces tumor cell apoptosis by downregulating the antioxidant transcription factor/cytoprotective molecule Nrf2/heme oxygenase-1 and inducing oxidative stress. Our results also showed that onvansertib can downregulate ATP-binding cassette transporters that are involved in drug resistance, and it resensitizes cabo-resistant RCC cells to apoptotic cell death. We further confirmed the effectiveness of the combination treatment through 3D spheroid culture as well as tumor xenograft models of RCC. Following combination treatment, there was increased drug-induced cytotoxicity and markedly reduced tumor growth in vivo. Together, our preclinical study identifies that cabo + onvansertib is an effective combination treatment to overcome c-Met–induced therapeutic resistance in RCC with translational potential.

  • Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress

    by Akash Sabarwal, Marc Machaalani, Laxminarayan Rawat, Johannes Wedel, Saba Tabasum, Yuzuru Sasamoto, Florian Buerger, Josie Ascione, Marc Eid, Karl Semaan, et al.


  • Open Access

    Honokiol in cancer: Roles in enhancing combination therapy efficacy and preventing post-transplant malignancies

    by Laxminarayan Rawat, Raghu Solanki, Rahul Kumar, Soumitro Pal, Akash Sabarwal

    Therapeutic resistance remains a significant challenge in cancer treatment, often resulting in relapse and poor outcomes. Conventional chemotherapies, such as cisplatin and paclitaxel, are frequently undermined by the development of chemoresistance and systemic toxicity. Targeted therapies, such as receptor tyrosine kinase (RTKs) inhibitors and monoclonal antibodies (mAbs), offer better specificity but face resistance over time. Combination therapies are being explored to improve efficacy and mitigate resistance. Honokiol, a biphenolic natural compound derived from Magnolia species, has emerged as a potential adjunct in combination therapies due to its anti-cancer, anti-inflammatory, and immunomodulatory properties. It enhances the efficacy of chemotherapies, such as cisplatin and paclitaxel, RTK inhibitors, such as cabozantinib and erlotinib, and mAbs, such as cetuximab. Notably, honokiol combined with mAbs has shown promise in pre-clinical studies by reactivating the immune system and reducing tumor growth in resistant models. In addition, honokiol aids in post-transplant cancer prevention by modulating immune responses, reducing tumor progression, and lowering the required dose of immunosuppressants, such as cyclosporine A and rapamycin. Pre-clinical studies in renal cell carcinoma (RCC), head and neck squamous cell carcinoma (HNSCC), and non-small cell lung cancer emphasize its potential to overcome resistance. Despite promising evidence, further clinical studies are needed to validate honokiol as a viable adjunct in combination therapies. While several reviews have focused on the effects of honokiol alone, there is a lack of comprehensive studies examining its potential in combination with other therapies. This review aims to fill this gap by offering critical insights into the role of honokiol as a candidate for combination therapy.


  • Top Cited Papers
    Open Access

    AXL signaling in cancer: from molecular insights to targeted therapies

    by Monika Yadav, Akansha Sharma, Ketki Patne, Saba Tabasum, Jyoti Suryavanshi, Laxminarayan Rawat, Marc Machaalani, Marc Eid, Rana P. Singh, Toni K. Choueiri, et al.

    AXL, a member of the TAM receptor family, has emerged as a potential target for advanced-stage human malignancies. It is frequently overexpressed in different cancers and plays a significant role in various tumor-promoting pathways, including cancer cell proliferation, invasion, metastasis, epithelial–mesenchymal transition (EMT), angiogenesis, stemness, DNA damage response, acquired therapeutic resistance, immunosuppression, and inflammatory responses. Beyond oncology, AXL also facilitates viral infections, including SARS-CoV-2 and Zika highlighting its importance in both cancer and virology. In preclinical models, small-molecule kinase inhibitors targeting AXL have shown promising anti-tumorigenic potential. This review primarily focuses on the induction, regulation and biological functions of AXL in mediating these tumor-promoting pathways. We discuss a range of therapeutic strategies, including recently developed small-molecule tyrosine kinase inhibitors (TKIs), monoclonal antibodies, and antibody–drug conjugates (ADCs), anti-AXL-CAR, and combination therapies. These interventions are being examined in both preclinical and clinical studies, offering the potential for improved drug sensitivity and therapeutic efficacy. We further discuss the mechanisms of acquired therapeutic resistance, particularly the crosstalk between AXL and other critical receptor tyrosine kinases (RTKs) such as c-MET, EGFR, HER2/HER3, VEGFR, PDGFR, and FLT3. Finally, we highlight key research areas that require further exploration to enhance AXL-mediated therapeutic approaches for improved clinical outcomes.


  • Open Access

    A novel combination therapy with Cabozantinib and Honokiol effectively inhibits c-Met-Nrf2-induced renal tumor growth through increased oxidative stress

    by Laxminarayan Rawat, Murugabaskar Balan, Yuzuru Sasamoto, Akash Sabarwal, Soumitro Pal


  • Open Access

    A Combination therapy using an mTOR inhibitor and Honokiol effectively induces autophagy through the modulation of AXL and Rubicon in renal cancer cells and restricts renal tumor growth following organ transplantation

    by Akash Sabarwal, Johannes Wedel, Kaifeng Liu, David Zurakowski, Samik Chakraborty, Evelyn Flynn, David M Briscoe, Murugabaskar Balan, Soumitro Pal

    Development of cancer, including renal cancer, is a major problem in immunosuppressed patients. The mTOR inhibitor Rapamycin (RAPA) is used as an immunosuppressive agent in patients with organ transplants and other immunological disorders; and it also has antitumorigenic potential. However, long-term use of RAPA causes reactivation of Akt, and ultimately leads to enhanced tumor growth. Honokiol (HNK) is a natural compound, which possesses both anti-inflammatory and antitumorigenic properties. In this study, we investigated the effect of a novel combination therapy using RAPA + HNK on allograft survival and post-transplantation renal tumor growth. We observed that it effectively modulated the expression of some key regulatory molecules (like Carabin, an endogenous Ras inhibitor; and Rubicon, a negative regulator of autophagy) that play important roles in tumor cell growth and survival. This combination induced toxic autophagy and apoptosis to promote cancer cell death; and was associated with a reduced expression of the tumor-promoting receptor tyrosine kinase AXL. Finally, we utilized a novel murine model to examine the effect of RAPA + HNK on post-transplantation renal tumor growth. The combination treatment prolonged the allograft survival and significantly inhibited post-transplantation tumor growth. It was associated with reduced tumor expression of Rubicon and the cytoprotective/antioxidant heme oxygenase-1 to overcome therapeutic resistance. It also downregulated the coinhibitory programmed death-1 ligand, which plays major role(s) in the immune escape of tumor cells. Together, this combination treatment has a great potential to restrict renal tumor growth in transplant recipients as well as other immunosuppressed patients.


  • Top Cited Papers

    Metabolic reprogramming in renal cancer: Events of a metabolic disease

    by Samik Chakraborty, Murugabaskar Balan, Akash Sabarwal, Toni K. Choueiri, Soumitro Pal


  • Open Access

    A Novel Combination Treatment with Honokiol and Rapamycin Effectively Restricts c-Met-Induced Growth of Renal Cancer Cells, and also Inhibits the Expression of Tumor Cell PD-L1 Involved in Immune Escape

    by Akash Sabarwal, Samik Chakraborty, Simran Mahanta, Selina Banerjee, Murugabaskar Balan, Soumitro Pal

    The mTOR inhibitor Rapamycin has tumor inhibitory properties; and it is also used as an immunosuppressive agent after organ transplantation. However, prolonged Rapamycin treatment re-activates Akt and can promote cancer growth. Honokiol is a natural compound with both anti-tumorigenic and anti-inflammatory properties. Here, we assessed the anti-tumor effects of Rapamycin and Honokiol combination in renal cell carcinoma (RCC). Receptor tyrosine kinase c-Met-mediated signaling plays a major role in RCC growth. We observed that compared with Rapamycin alone, Rapamycin + Honokiol combination can effectively down-regulate c-Met-induced Akt phosphorylation in renal cancer cells; and it markedly inhibited Ras activation and cell proliferation and promoted G1 phase cell cycle arrest. The combination treatment significantly induced ROS generation and cancer cell apoptosis even when c-Met is activated. Importantly, Honokiol, but not Rapamycin, decreased c-Met-induced expression of the co-inhibitory molecule PD-L1, implied in the immune escape of renal cancer cells. In mouse renal cancer cells and Balb/c splenocytes co-culture assay, Rapamycin + Honokiol markedly potentiated immune-cell-mediated killing of cancer cells, possibly through the down-regulation of PD-L1. Together, Honokiol can effectively overcome the limitation of Rapamycin treatment alone; and the combination treatment can markedly restrict the growth of RCC, with particular importance to post-transplantation renal cancer.


  • Signaling Molecules in Posttransplantation Cancer

    by Murugabaskar Balan, Samik Chakraborty, Soumitro Pal


  • Open Access

    Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1

    by Samik Chakraborty, Murugabaskar Balan, Evelyn Flynn, David Zurakowski, Toni K. Choueiri, Soumitro Pal

    Any imbalance between reactive oxygen species (ROS) generation and the anti-oxidant capacity lead to cellular oxidative stress. Many chemotherapeutic agents mediate their cytotoxic functions through the generation of ROS. c-Met, a receptor tyrosine kinase, is over-expressed in renal cancer and plays very crucial role(s) in its growth and survival. Here, we show that c-Met activation protected renal cancer cells from ROS, oxidative stress and cytotoxicity induced by the anti-cancer agent sorafenib (used for renal cancer treatment); and it markedly attenuated sorafenib-induced DNA damage. Activated c-Met promoted the anti-apoptotic proteins (Bcl-2 and Bcl-xL) and inhibited apoptotic cleaved caspase-3. We found that the cytoprotective function of c-Met against sorafenib-induced ROS generation and apoptosis was mediated primarily through the activation of anti-oxidant Nrf2-HO-1. c-Met promoted the nuclear localization of Nrf2 and hindered its binding with the inhibitory protein Keap1. Silencing of Nrf2 attenuated the protective action of c-Met against sorafenib-induced oxidative stress. To evaluate the physiological significance of our findings, in a tumor xenograft model, we observed that a combination treatment with pharmacological inhibitors of c-Met and it’s anti-oxidant downstream effecter HO-1 markedly reduced the growth of renal tumor in vivo; it increased the oxidative stress, DNA damage and apoptotic markers in the tumor xenografts, along with reduced tumor vessel density. Our observations indicate that the c-Met-Nrf2-HO-1 pathway plays a vital role in relieving ROS-mediated oxidative stress of renal tumors. Targeting this pathway can significantly increase the oxidative stress to promote apoptotic death of cancer cells.